Literature DB >> 2991962

A beta-carboline antagonizes benzodiazepine actions but does not precipitate the abstinence syndrome in cats.

E Ongini, M Marzanatti, F Bamonte, A Monopoli, V Guzzon.   

Abstract

The beta-carbolines, which are potent ligands for benzodiazepine receptors, antagonize the pharmacological actions of benzodiazepines. In the cat, the stable beta-carboline derivative methylamide-beta-carboline-3-carboxylate, FG 7142, and the specific benzodiazepine antagonist Ro 15-1788 reversed behavioral and electroencephalographic (EEG) changes produced by a single dose of diazepam. Surprisingly, the beta-carboline did not elicit signs of withdrawal when given after 22 days of a daily dose regimen of diazepam, while Ro 15-1788 precipitated an acute abstinence syndrome largely characterized by tremors, increased muscle tone, back arching, myoclonic jerks and pupil dilatation. Unlike Ro 15-1788, the beta-carboline produced effects of its own such as behavioral states of arousal and fearfulness. These findings indicate that the beta-carboline functionally interacts with benzodiazepine receptors in a manner unlike that seen with typical agonists and antagonists.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991962     DOI: 10.1007/bf00431697

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  25 in total

1.  Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors.

Authors:  R Dorow; R Horowski; G Paschelke; M Amin
Journal:  Lancet       Date:  1983-07-09       Impact factor: 79.321

2.  Precipitated withdrawal by a benzodiazepine receptor antagonist (Ro 15-1788) after 7 days of diazepam.

Authors:  S E Lukas; R R Griffiths
Journal:  Science       Date:  1982-09-17       Impact factor: 47.728

3.  Intrinsic and antagonistic effects of beta-carboline FG 7142 on behavioral and EEG actions of benzodiazepines and pentobarbital in cats.

Authors:  E Ongini; C Barzaghi; M Marzanatti
Journal:  Eur J Pharmacol       Date:  1983-11-11       Impact factor: 4.432

4.  Urinary and brain beta-carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors.

Authors:  C Braestrup; M Nielsen; C E Olsen
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

5.  Benzodiazepine receptor-mediated experimental "anxiety" in primates.

Authors:  P T Ninan; T M Insel; R M Cohen; J M Cook; P Skolnick; S M Paul
Journal:  Science       Date:  1982-12-24       Impact factor: 47.728

6.  Physical dependence on diazepam and lorazepam in the dog.

Authors:  L F McNicholas; W R Martin; S Cherian
Journal:  J Pharmacol Exp Ther       Date:  1983-09       Impact factor: 4.030

7.  Differential effects of benzodiazepines on EEG activity and hypnogenic mechanisms of the brain stem in cats.

Authors:  M Mariotti; E Ongini
Journal:  Arch Int Pharmacodyn Ther       Date:  1983-08

8.  A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizers, beta-carbolines, and phenobarbitone.

Authors:  P Polc; E P Bonetti; R Schaffner; W Haefely
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

9.  Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors.

Authors:  A Guidotti; C M Forchetti; M G Corda; D Konkel; C D Bennett; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

10.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

View more
  1 in total

1.  Precipitated withdrawal in squirrel monkeys after repeated daily oral administration of alprazolam, diazepam, flunitrazepam or oxazepam.

Authors:  J R Martin; J L Moreau; F Jenck
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.